Phase
Condition
Opioid Use Disorder
Stimulant Use Disorder
Treatment
Hydromorphone
Buprenorphine/naloxone
Clinical Study ID
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Opioid Use Disorder (OUD) as defined by the Diagnostic and Statistical Manual ofMental Disorders-5 diagnostic criteria;
Individuals seeking Opioid Agonist Treatment (OAT);
Be 19 years of age or older;
Be willing and able to adhere to the study protocol and follow-up schedule;
Be able to provide written informed consent to participate in the clinical trial.
If female and of childbearing potential, agree to use an effective method of birthcontrol approved by the study investigators throughout the study.
Exclusion
Exclusion Criteria:
Diagnosis of severe medical or psychiatric conditions contraindicated forbuprenorphine/naloxone or hydromorphone treatment;
Anticipated deterioration of health due to discontinuation of medications that arecontraindicated with buprenorphine/naloxone and/or hydromorphone;
Positive pregnancy test for women of childbearing potential;
Methadone use in the past 5 days;
Buprenorphine use in the past 5 days;
Known allergy or sensitivity to buprenorphine/naloxone and/or hydromorphone;
Anticipation that the patient may need to initiate pharmacological treatment duringthe trial that is deemed unsafe by the study physician or could prevent studycompletion;
Unwilling or unable to use an effective method of birth control approved by thestudy investigators throughout the study.
Study Design
Study Description
Connect with a study center
Vancouver General Hospital
Vancouver, British Columbia V5Z 1M9
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.